Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia

被引：16
|
作者：
Castillo, Jorge J. [1 ,2 ]
Gustine, Joshua N. [1 ]
Meid, Kirsten [1 ]
Dubeau, Toni E. [1 ]
Xu, Lian [1 ]
Yang, Guang [1 ,2 ]
Hunter, Zachary R. [1 ]
Advani, Ranjana [3 ]
Palomba, Lia [4 ]
Treon, Steven P. [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 10期
关键词：
MYD88;
D O I：
10.3324/haematol.2018.191999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E466 / E468
页数：3
相关论文
共 50 条
  • [41] Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial
    Treon, Steven P.
    Meid, Kirsten
    Gustine, Joshua
    Bantilan, Kurt S.
    Dubeau, Toni
    Severns, Patricia
    Yang, Guang
    Xu, Lian
    Patterson, Christopher
    Ghobrial, Irene M.
    Laubach, Jacob
    Hunter, Zachary
    Castillo, Jorge J.
    Palomba, Maria L.
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [42] CXCR4 mutational status does not impact outcomes in patients with Waldenstrom macroglobulinemia treated with proteasome inhibitors
    Castillo, Jorge J.
    Gustine, Joshua N.
    Meid, Kirsten
    Flynn, Catherine A.
    Demos, Maria G.
    Guerrera, Maria L.
    Jimenez, Cristina
    Kofides, Amanda
    Liu, Xia
    Munshi, Manit
    Tsakmaklis, Nicholas
    Patterson, Christopher J.
    Xu, Lian
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : E95 - E98
  • [43] Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's Macroglobulinemia treated with Fludarabine
    Costa, P
    Luzzati, R
    Nicolato, A
    Perboni, G
    Scalzini, A
    Lazzarini, L
    Forghieri, ME
    Aitini, E
    Zinzani, PL
    LEUKEMIA & LYMPHOMA, 1998, 28 (5-6) : 617 - 620
  • [44] CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors
    Castillo, Jorge J.
    Gustine, Joshua
    Demos, Maria
    Keezer, Andrew
    Meid, Kirsten
    Dubeau, Toni
    Chan, Gloria G.
    Chen, Jiaji
    Guerrera, Maria Luisa
    Kofides, Amanda
    Munshi, Manit
    Tsakmaklis, Nicholas
    Liu, Xia
    Xu, Lian
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    BLOOD, 2019, 134
  • [45] A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenstrom's macroglobulinemia
    Patel, Dave
    Sidana, Megan
    Mdluli, Xolani
    Patel, Vallari
    Stapleton, Ann
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1917 - 1921
  • [46] CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
    Castillo, Jorge J.
    Xu, Lian
    Gustine, Joshua N.
    Keezer, Andrew
    Meid, Kirsten
    Dubeau, Toni E.
    Liu, Xia
    Demos, Maria G.
    Kofides, Amanda
    Tsakmaklis, Nicholas
    Chen, Jiaji G.
    Munshi, Manit
    Guerrera, Maria L.
    Chan, Gloria G.
    Patterson, Christopher J.
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (03) : 356 - 363
  • [47] CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstrom macroglobulinemia
    Gustine, Joshua N.
    Xu, Lian
    Tsakmaklis, Nicholas
    Demos, Maria G.
    Kofides, Amanda
    Chen, Jiaji G.
    Liu, Xia
    Munshi, Manit
    Guerrera, Maria Luisa
    Chan, Gloria G.
    Patterson, Christopher J.
    Keezer, Andrew
    Meid, Kirsten
    Dubeau, Toni
    Yang, Guang
    Hunter, Zachary R.
    Treont, Steven P.
    Castillo, Jorge J.
    BLOOD ADVANCES, 2019, 3 (19) : 2800 - 2803
  • [48] IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS
    Treon, S.
    Tripsas, C.
    Meid, K.
    Warren, D.
    Varma, G.
    Green, R.
    Argyropoulos, K.
    Yang, G.
    Cao, Y.
    Xu, L.
    Patterson, C.
    Rodig, S.
    Zehnder, J.
    Aster, J.
    Harris, N. L.
    Kanan, S.
    Ghobrial, I.
    Laubach, J.
    Hunter, Z.
    Salman, Z.
    Cheng, M.
    Li, J.
    Clow, F.
    Graef, T.
    Castillo, J.
    Palomba, M. L.
    Advani, R.
    HAEMATOLOGICA, 2015, 100 : 311 - 311
  • [49] Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study
    Ghobrial, Irene M.
    Harousseau, Jean-Luc
    Treon, Steven P.
    Harris, Brianna
    Lin, Courtney E.
    Yuan, Zheng
    Benhadji, Karim
    Wooldridge, James E.
    Leblond, Veronique
    BLOOD, 2009, 114 (22) : 1488 - 1488
  • [50] Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib
    Castillo, Jorge J.
    Gustine, Joshua
    Demos, Maria
    Keezer, Andrew
    Meid, Kirsten
    Chan, Gloria G.
    Chen, Jiaji G.
    Guerrera, Maria Luisa
    Kofides, Amanda
    Munshi, Manit
    Tsakmaklis, Nicholas
    BLOOD, 2019, 134
12345